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Highlights 
 Continuous dosing of piperacillin in critical illness does not yield a high sustained 
target. 
 Large variability in concentrations is seen in continuous dosing of piperacillin. 
 Higher continuous dosing of piperacillin and therapeutic drug monitoring is 
needed. 
ABSTRACT 
Optimal dosing of -lactam antibiotics in critically ill patients is a challenge given the 
unpredictable pharmacokinetic profile of this patient population. Several studies have 
shown intermittent dosing to often yield inadequate drug concentrations. Continuous 
dosing is an attractive alternative from a pharmacodynamic point of view. This study 
evaluated whether, during continuous dosing, piperacillin concentrations reached and 
maintained a pre-defined target in critically ill patients. Adult patients treated with 
piperacillin by continuous dosing in the intensive care unit of a university medical centre 
in The Netherlands were prospectively studied. Total and unbound piperacillin 
concentrations drawn at fixed time points throughout the entire treatment course were 
determined by liquid chromatography–tandem mass spectrometry. A pharmacokinetic 
combined target of a piperacillin concentration ≥80 mg/L, reached within 1 h of starting 
study treatment AND maintained throughout the treatment course, was set. Eighteen 
patients were analysed. The median duration of monitored piperacillin treatment was 60 
h (interquartile range, 33–96 h). Of the 18 patients, 5 (27.8 %) reached the combined 
target; 15 (83.3%) reached and maintained a less strict target of >16 mg/L. In this 
patient cohort, this dosing schedule was insufficient to reach the pre-defined target. 
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Depending on which target is to be met, a larger initial cumulative dose is desirable, 
combined with therapeutic drug monitoring. 
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1. Introduction 
Infections, both community-acquired and nosocomial, are a constant source of morbidity 
and mortality in critically ill patients [1]. -Lactams, with or without a -lactamase 
inhibitor, are the most prescribed group of antibiotics in this setting [2,3]. Guidelines for 
the management of severe sepsis and septic shock advocate the initiation of antibiotics 
as soon as possible, using broad-spectrum antibiotics that penetrate in adequate 
concentrations at the presumed site of infection, ensuring optimal activity against all 
likely pathogens [4]. Choosing appropriate therapy is crucial, as inadequate 
antimicrobial treatment is an important determinant of poor outcome [5]. Optimal dosing 
is equally important because inadequate dosing leads to treatment failure and antibiotic 
resistance [6]. 
 
Piperacillin/tazobactam (TZP) is a widely used -lactam/-lactamase inhibitor 
combination. The effectiveness of piperacillin is determined by the time the unbound 
plasma concentration (fT) is higher than the minimum inhibitory concentration (MIC) of 
the causative bacteria (fT>MIC) [7]. A maximum kill rate is achieved at a free drug 
concentration of ca. 4 MIC [8], with no additional effect above this concentration. There 
is no relevant post-antibiotic effect against Gram-negative micro-organisms [9]. Dosing 
regimens have traditionally been based upon pharmacokinetics as tested in vitro, in 
animal models and in healthy volunteers [6,10–12]. However, in critical illness, several 
complex mechanisms induce an altered pharmacokinetic profile owing to, for example, 
an increase in volume of distribution and an alteration in renal clearance [11]. Numerous 
studies have shown inadequate drug concentrations in critically ill patients treated with 
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-lactams using conventional dosing regimens [13–20]. In particular, augmented renal 
clearance, as might occur during the hyperdynamic stage of sepsis, appears to be a risk 
factor for failing to reach adequate -lactam drug levels [15–19]. 
 
From a pharmacodynamic point of view, continuous infusion is an attractive alternative 
to conventional intermittent dosing of -lactams. This is also supported by clinical 
studies [21–25], The critical care population is likely to gain the most benefit from 
continuous dosing as this group tends to harbour pathogens with higher MICs [26] and 
to have an unpredictable pharmacokinetic profile [11]. Although high-quality randomised 
trials showing a survival benefit are still lacking, in a recent meta-analysis of individual 
patient data from three randomised trials, treatment with -lactam antibiotics by 
continuous infusion was associated with lower mortality compared with intermittent 
dosing in critically ill patients with severe sepsis [24]. Continuous dosing of TZP, 
however, is not yet widely employed in European intensive care units (ICUs) [27]. 
 
This prospective study was conducted to evaluate whether, during continuous dosing, 
piperacillin concentrations reach and maintain a high target concentration in critically ill 
patients, likely to cover most problematic pathogens such as Pseudomonas aeruginosa. 
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2. Materials and methods 
2.1. Study design and study population 
This prospective, observational, single-centre, cohort study was conducted in the 
Department of Critical Care of University Medical Center Groningen (UMCG) 
(Groningen, The Netherlands) between December 2013 and January 2015. The study 
was approved by the Medical Ethics Board of this hospital. Written informed consent 
was obtained from the patient or their next of kin. Patients were eligible for inclusion at 
the start of treatment with TZP for suspected or proven infection. Start of treatment was 
at the discretion of the treating physician. Inclusion criteria were: indication for treatment 
with TZP; admitted to the ICU; age ≥18 years; and able to give informed consent or 
legal representative able to give informed consent. All patients had an indwelling arterial 
line for reasons outside the study protocol. Exclusion criteria were: pregnancy; severe 
anaemia; use of renal replacement therapy; and contra-indications to continuous 
infusion. Patients already started on TZP by intermittent dosing (e.g. on the ward, 
before ICU admission) were included if no more five doses had been given; continuous 
dosing was started directly after a next bolus. 
 
All patients, regardless of kidney function, received a loading dose of 4 g/0.5 g TZP 
(Piperacillin/Tazobactam Fresenius Kabi 4g/0.5g powder for solution for infusion; 
LABESFAL Fresenius Kabi Group, Santiago de Besteiros, Portugal) infused over 20 
min. Continuous dosing was started directly after the loading dose in all patients using a 
syringe pump (Alaris® GH perfusor; CareFusion, Rolle, Switzerland). The first hour of 
starting treatment, including infusion of the loading dose over 20 min directly followed by 
Page 7 of 30
 8 
continuous infusion, was considered the loading phase. The next phase, from 1 h after 
the start of treatment, was referred to as the maintenance phase. The sample drawn at 
1 h after the start of treatment was considered as part of the maintenance phase. The 
dosing schedule for continuous infusion in the maintenance phase was adjusted to renal 
function [assessed by calculation of creatinine clearance (CLCr) over 24-h intervals 
using the equation: Urine creatinine (mmol/L)  Urine volume (mL)/time (min)  Serum 
creatinine (mmol/L) (UCreat  UVol/time  SCreat); or, when parameters not were 
available, estimated using the Modification of Diet in Renal Disease (MDRD) formula for 
estimated glomerular filtration rate]. Renal function was recorded on the day of starting 
treatment with TZP in the context of the study. 
 
Patients with a CLCr > 40 mL/min received a continuous infusion of 12/1.5 g TZP every 
24 h. Patients with a CLCr of 20–40 mL/min received a continuous dose of 8/1 g on Day 
1 and 12/1.5 g from Day 2 onwards. Patients with a CLCr < 20 mL/min received a 
continuous dose of 8/1 g from Day 1. Blood samples were drawn at the start of 
treatment in the context of the study on Day 1 and then at 20 min after the start of 
treatment (directly after the loading dose); subsequent samples were drawn at 40 min 
and at 1, 2, 4, 8, 12 and 24 h after the start of treatment; from Day 2, samples were 
drawn every 12 h for a maximum period of 2 weeks or until treatment with TZP was 
stopped. Samples were centrifuged and were frozen at –20 C, to be processed in 
batch by the Department of Clinical Pharmacy and Pharmacology of UMCG. Patient 
characteristics included demographic and clinical data, assessment of illness severity 
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reflected by the Acute Physiology and Chronic Health Evaluation (APACHE) IV score, 
and laboratory investigations. 
 
2.2. Definition of pharmacokinetic/pharmacodynamic (PK/PD) target 
A ‘strict’ target was chosen based on the notion that for -lactams, a maximum kill rate 
is achieved at a free (unbound) drug concentration of ca. 4 the MIC of a causative 
organism, with no additional effect above this concentration [8,28] and the absence of a 
relevant post-antibiotic effect against Gram-negative organisms [9]. Pseudomonas 
aeruginosa was chosen as a possible causative micro-organism in consideration of a 
‘worst-case scenario’, with an MIC clinical breakpoint of 16 mg/L 
(http://www.eucast.org/clinical_breakpoints/; accessed 21 May 2016), to cover most 
problematic pathogens [29] in an empirical treatment setting. 
 
The pre-defined PK/PD target was thus set at 100%T≥5xMIC (percentage of time of 
dosing interval during which the total concentration exceeds 5 MIC), assuming 20–
30% protein binding [30,31], implying a target of 4  16 = 64 mg/L for unbound and 5  
16 = 80 mg/L for total piperacillin concentration. This target is in line with targets set by 
other research groups considered experts in the field [14,32] as well as reviews 
addressing the pharmacokinetics of -lactams [8,33,34]. This target was to be met from 
1 h after the start of treatment in the context of the study, i.e. during the maintenance 
phase; 1 h after start of the last bolus infusion directly followed by continuous infusion, 
and to be maintained thereafter; we will refer to this as a combined target (target 
reached within 1 h AND maintained thereafter). Reaching a target of >16 mg/L 
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piperacillin in the maintenance phase, i.e. at 1 h after the start of treatment and 
maintained thereafter, 100%T>1xMIC, was also determined. For unbound concentrations, 
a target of ≥4 MIC (64 mg/L) was set. Target attainment was evaluated at sample level 
as well as in individual patients. Whether the target concentration was reached at 1 h 
after start of treatment in the context of the study was also assessed. 
 
2.3. Bioanalysis of piperacillin serum concentrations 
Total serum concentrations of piperacillin were determined at the Laboratory for Clinical 
Toxicology and Drugs Analysis of the Department of Clinical Pharmacy and 
Pharmacology of the UMCG using a validated liquid chromatography–tandem mass 
spectrometry (LC-MS/MS) assay. In brief, all analyses were performed on a triple 
quadrupole LC-MS/MS system (Thermo Scientific, San Jose, CA) with a FinniganTM 
Surveyor® LC pump and a FinniganTM Surveyor® autosampler (Thermo Scientific). The 
mobile phase consisted of an aqueous buffer (containing ammonium acetate 5 g/L, 
acetic acid 35 mL/L and trifluoroacetic acid 2 mL/L water), water and acetonitrile. For 
chromatography, an Atlantis® HILIC Silica analytical column (2.1  100 mm, 3 m) 
(Waters, Etten-Leur, The Netherlands) was used. A simple procedure for protein 
precipitation was used to prepare the samples. For piperacillin, the transition m/z 518.0 
to 114.8 (collision energy 51 eV) was measured with a scan width of 0.5 m/z. The 
calibration curve ranged from 0.5–80 mg/L for piperacillin with a correlation coefficient of 
0.99941. Within-run coefficient of variation (CV) ranged from 2.5–12.9% and between-
run CV ranged from 5.9–12.5%. Bias ranged from –13.4% at the lower limit of 
quantification (LLOQ) level to 10.1% at high level. Unbound piperacillin concentrations 
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were determined in all patients at 1 h and 12 h after the start of treatment. Samples 
were prepared by ultrafiltration of the corresponding serum samples; 10 L of human 
serum was directly transferred into the upper reservoir of the centrifuge filters 
(Nanosep® 30 K Omega centrifugal device; Pall Corp.) and 200 L of the internal 
standard solution was added. The centrifuge filters were closed and the samples were 
briefly homogenised using a vortex mixer. Filtration was done by centrifugation for 10 
min at 12 000  g. 
 
2.4. Statistical analysis 
Target attainment was presented as a percentage; percentage of time at or above 
target per subject and percentage reaching target at group level. Continuous 
parameters were depicted in absolute numbers and either mean ± standard deviation 
(S.D.) or median [interquartile range (IQR)], depending on the distribution. Categorical 
data were depicted as percentage per/in category. Outliers in concentration data were 
investigated per patient in the maintenance phase (i.e. from 1 h after the start of 
treatment and onwards) and were defined as values outside the range of 3  IQR + Q3 
to Q1 – 3  IQR; these were subsequently excluded from the variability analysis and 
were assessed for exclusion in the target attainment analysis. In the boxplot, they were 
investigated per sampling period. To quantify within-patient variability, a CV per patient 
was calculated, defined as a patient’s individual S.D. divided by the mean of this 
patient’s concentrations, as measured during the maintenance phase, multiplied by 
100%. The median, mean and range of these individual CVs were calculated. To 
quantify between-patient variability, we chose to calculate a CV for available 
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concentrations measured at 40 min and at 12, 24, 48 and 60 h after the start of 
treatment in all patients, respectively. A median, mean and range of these five CVs 
were calculated. Statistical analyses were performed using SPSS Statistics for Windows 
v.22 (IBM Corp., Armonk, NY). 
 
3. Results 
3.1. Patient characteristics 
Twenty patients were included in the study; two patients were excluded because of 
breach of protocol. Baseline characteristics and clinical outcome data of this typical ICU 
population are presented in Table 1. Almost all patients required vasopressors and 
mechanical ventilation (94.4% and 88.9%, respectively). The median length of ICU stay 
was 9 days (IQR, 3–13.3 days). Four patients (22.2%) died in the ICU; none of the other 
patients died in hospital. Causes of death in the four patients were decompensated liver 
cirrhosis with subsequent multi-organ failure, severe traumatic brain injury, massive 
intrathoracic bleeding after oesophageal resection complicated by anastomotic leakage, 
and sepsis following chronic osteomyelitis. 
 
3.2. Piperacillin concentration data 
In the 18 patients, 53 samples taken during the loading phase and 175 samples taken 
during the maintenance phase were available for analysis. The median follow-up 
(duration of piperacillin treatment including sampling of piperacillin concentrations) was 
60 h (IQR, 33–96 h). Three outliers were excluded from the analysis. Two outliers were 
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included as they represented very high values at the beginning of the sampling period 
most likely due to interindividual variability or to procedural reasons. 
 
Of 172 samples in the maintenance phase, 73 (42.4 %) were at or above the pre-
defined target concentration of 80 mg/L; 168 (97.7%) were >16 mg/L. In 16 (88.9%) of 
18 patients a concentration of ≥80 mg/L was reached within 1 h after the start of 
treatment. However, in only 5 (27.8%) of 18 analysed patients was a concentration of 
≥80 mg/L maintained (i.e. reached the combined target). Two patients (11.1%) never 
reached a concentration ≥80 mg/L. On patient level, a median of 39.6% of samples per 
patient in the maintenance phase were ≥80 mg/L (IQR, 15.5–100.0 mg/L). 
 
All patients had a concentration >16 mg/L within 1 h after the start of treatment. In 15 
patients (83.3%), a concentration >16 mg/L was maintained. The data are summarised 
in Table 2 and Fig. 1. 
 
Two of the four deceased patients had piperacillin levels ≥80 mg/L at any time during 
treatment, from 1 h after the start of treatment. 
 
All of the patients with a CLCr < 50 mL/min (7 patients) reached a piperacillin 
concentration ≥80 mg/L within 1 h of starting treatment, and 3 (42.9%) of the 7 
maintained a concentration ≥80 mg/L. In patients with a CLCr ≥ 50 mL/min (11 patients), 
9 (81.8%) reached a piperacillin concentration ≥80 mg/L within 1 h of starting treatment 
and 2 (18.2%) of 11 maintained a concentration ≥80 mg/L. Measurement of CLCr by 
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UCreat  UVol/time  SCreat was available in 13 of 18 patients; in 5 patients renal 
function was estimated using the MDRD formula. 
 
Unbound piperacillin concentrations assessed at 1 h after the start of treatment (total, 
18 samples in 18 patients) were ≥64 mg/L (4 MIC) in 16 (88.9%) of 18 samples and 
were >16 mg/L in all 18 samples (100%). Unbound piperacillin concentrations assessed 
at 12 h after the start of treatment (total, 18 samples in 18 patients) were ≥64 mg/L in 7 
(38.9%) of 18 samples and were >16 mg/L in all 18 samples (100%). The median 
fraction unbound was 0.93 [IQR, 0.89–0.97]. 
 
3.3. Variability 
The median within-patient CV was 32.3% (mean, 39.7%), with a range of 10.3–99.2%. 
 
Concentrations analysed at 40 min and at 12, 24, 48 and 60 h after the start of 
treatment for between-patient variability were available for 18, 18, 15, 10 and 10 
patients, respectively. Median CV for the five time points was 71.8% (mean, 78.7%), 
with a range of 55.4–99.9%. 
 
Five outliers were excluded from the calculation of the within-patient and between-
patient CV. 
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4. Discussion 
To the best of our knowledge, this is the first observational study describing piperacillin 
concentrations over the entire treatment period in a heterogeneous group of adult ICU 
patients treated with continuous dosing. As expected, most patients showed a rapid rise 
in piperacillin concentration after receiving a loading dose; indeed, the vast majority 
(88.9%) reached the pre-defined target concentration of 80 mg/L within 1 h after the 
start of treatment. Over the course of time, however, despite continuous administration, 
a large inter-individual and intra-individual variability in piperacillin concentrations was 
observed in this population, with a trend toward lower concentrations over time (Fig. 1). 
This large variability was also found in a recent study evaluating extended, i.e. 
prolonged but not continuous, infusion of piperacillin in ICU patients [35]. 
 
Overall, the combined target of a total piperacillin concentration ≥80 mg/L reached 
within 1 h after starting study treatment AND maintained throughout the treatment 
course was met in only 27.8% of patients. Large recent studies analysing conventional 
dosing of -lactams showed similar results, where pre-defined targets were not met in a 
large proportion of patients [13,15]. 
 
Total and unbound piperacillin concentrations were compared in a subset of samples; 
as expected, the difference between free and total concentrations was small. Because 
this difference is small, the cheaper and easier total concentration will suffice, as 
employed by others [36]. 
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Toxic levels of piperacillin are not well defined in the literature. No clinical signs of 
overdosing (convulsions) were seen in the current cohort. 
 
Although a matter of debate, we chose an ‘aggressive’ combined target of 100%T≥5xMIC 
for total piperacillin concentration in the maintenance phase, with a presumed protein 
binding of ca. 20–30% for piperacillin, using the piperacillin MIC breakpoint for P. 
aeruginosa. Within the set definition, the target concentration was to be met within a 
small timeframe, i.e. 1 h. PK/PD indices vary widely in the literature, ranging from 
100%fT>MIC to 40–100%fT>4xMIC for unbound piperacillin concentrations [37]. There is no 
conclusive evidence as to which target is required for an optimal therapeutic effect. 
Altered pharmacokinetics in the critical care patient and possible infection by pathogens 
with an MIC at or near the resistant breakpoint increase the risk of underdosing [11]. We 
chose the strict combined target to ensure maximum killing of most problematic (Gram-
negative) pathogens in a primarily empirical treatment setting. Supplementary Table S1 
illustrates the consequence of different target levels. Obviously, target attainment is 
influenced by the MIC judged to be relevant as dictated by local resistance patterns. A 
less strict target of 100%T>MIC was still not met in 16.7% of patients (Table 2). Assuming 
the great majority of Gram-negatives to have an MIC < 16 mg/L would allow to start 
using the ‘one size fits all’ continuous dosing schedule, as was done in this study. 
Sampling for therapeutic drug monitoring (TDM) could then be done at any time during 
the maintenance phase to enable proper dose adjustment; in combination with culture 
results, assuming that these are available, this could mean lowering the dosing 
schedule in a substantial proportion of the population. However, if more resistant 
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pathogens are cultured or if expected higher targets have to be met, the perspective 
changes. This would then make a case for TDM throughout the course of treatment. 
Piperacillin has a large therapeutic range. In this study, lower piperacillin concentrations 
were found over the course of treatment and a suboptimal target was attained, even 
when a lower target of 100%T>MIC was set. Therefore, it seems safe and logical to start 
a larger cumulative dosing regimen, e.g. 16 g daily of piperacillin infused over 24 h, 
preceded by a loading dose of 4 g of piperacillin infused over 20 min, in a ‘hit fast, hit 
high’ strategy, followed, if possible, by downgrading based on TDM and cultured 
causative micro-organism. 
 
In our view, strengths of this study include it being the first observational study 
describing piperacillin concentrations in adult ICU patients treated with continuous 
dosing over the entire treatment period. Furthermore, total as well as unbound 
concentrations were assessed. 
 
This study also has some limitations. Only piperacillin concentrations were analysed, 
not tazobactam. Piperacillin and tazobactam pharmacokinetics are not identical and in 
patients with renal function loss tazobactam overdose might occur [38]. As outlined in 
the methods, in several patients piperacillin treatment was started intermittently before 
start of the study. As treatment was given in intervals of 8 h, in these patients it was still 
relevant to assess whether the target was met after the start of study treatment, i.e. 
continuous dosing directly after a bolus infused over 20 min. 
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Some samples were excluded from analysis as they were identified as outliers. 
Measurement of CLCr by UCreat  UVol/time  SCreat was not available in all patients; 
in 5 of 18 patients renal function was estimated using the MDRD formula. In this 
analysis, renal function measured/estimated on the first study day was used. In daily 
practice, however, in most patients CLCr was measured and in no alteration in dosing 
due to significant changes in CLCr was needed. Patients with renal replacement therapy 
or other extracorporeal support were excluded because in these patients we considered 
kinetics to be so complicated that this deserves a separate study. The sample size was 
too small to identify subgroups that would benefit most from TDM. 
 
5. Conclusions 
These data show a large variability in piperacillin concentrations in critically ill patients 
treated with continuous dosing following a loading dose. With the dosing schedule used, 
the target set to reach 5 MIC of P. aeruginosa during the entire continuous infusion 
from 1 h after the start of treatment could not be attained. Very low levels were rare. 
From a pharmacokinetic point of view, continuous dosing is more advantageous than 
intermittent dosing. However, optimising this dosing strategy merits further attention, as 
shown by the current data. Depending on which target is to be met, a larger initial 
cumulative dose is desirable, combined with TDM, to avoid subtherapeutic drug 
concentrations. Formal proof-of-effect of antibiotic concentrations on survival in 
randomised controlled studies is still lacking, but it seems both logical and feasible to try 
to achieve optimal dosing. 
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Fig. 1 Total piperacillin concentration over time, from the start of treatment, group level. 
 
Dark line middle of box = median; whiskers represent 1.5  IQR; circles represent outliers between 1.5–3 
 IQR; star represents outlier >3  IQR; horizontal lines (16 mg/L and 80 mg/L) represent target 
concentrations discussed in text. The number of data used per boxplots is given above the respective 
boxplot. IQR, interquartile range. 
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Table 1 Baseline characteristics and clinical outcome data of patients include in the 
study (n = 18) 
Variable Median [IQR] {range} or n (%) 
Age (years) 61.5 [54–66.3] {19–72} 
Male sex 14 (77.8) 
BMI (kg/m2) 25.1 [22.6–29.7] {21.6–41.2} 
Patient category  
Medical 6 (33.3) 
Surgery 10 (55.6) 
Trauma 2 (11.1) 
Presumed/proven site of infection  
Intra-abdominal 12 (66.7) 
Respiratory 3 (16.7) 
Skin/soft tissue 1 (5.6) 
Unknown 2 (11.1) 
Co-morbidities a  
None 5 (27.8) 
Solid malignancy 6 (33.3) 
Haemato-oncology 1 (5.6) 
Cardiovascular 6 (33.3) 
Chronic pulmonary 2 (11.1) 
Inflammatory bowel disease/diverticulitis 2 (11.1) 
Cushing’s syndrome 2 (11.1) 
Liver cirrhosis 1 (5.6) 
Diabetes 1 (5.6) 
APACHE IV score b 64 [56–85] {24–128} 
Mechanical ventilation 16 (88.9) 
Use of vasopressors 17 (94.4) 
Measured CLCr (mL/min) c 62.5 [26.8–116.8] {3.4–183.8} 
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ICU length of stay (days) 9 [3–13.3] {2–75} 
ICU mortality 4 (22.2) 
Hospital mortality 4 (22.2) 
IQR, interquartile range; BMI, body mass index; APACHE, Acute Physiology and 
Chronic Health Evaluation; CLCr, creatine clearance; ICU, intensive care unit. 
a More than one variable per patient possible. 
b Available in 13 patients. 
c Available in 13 patients. 
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Table 2 Total piperacillin concentration (mg/L) from 1 h after the start of treatment 
(maintenance phase) and target attainment 
 N (% of 
172 
samples) 




Follow-up (h) a   60 33–96 
Concentration (n = 172 samples) 
(mg/L) 
  65.7 4.9–131.8 
Total range, 
8.7–284.9 
Cmax (n = 18 patients) (mg/L)   144.5 119.4–217.3 
Cmin (n = 18 patients) (mg/L)   46.2 28.7–87.2 
C ≥ 80 mg/L from 1 h after start of 
treatment 
73 (42.4%)    




   
% of samples with C ≥ 80 mg/L 
from 1 h after start of treatment, 
per patient (n = 18) 
  39.6 15.5–100 
% of samples with C ≥ 16 mg/L 
from 1 h after start of treatment, 
per patient (n = 18) 
  100 100–100 
C ≥ 80 mg/L reached within 1 h 
after start of treatment 
 16 (88.9%)   
C > 16 mg/L reached within 1 h 
after start of treatment 
 18 (100%)   
C ≥ 80 mg/L reached within 1 h 
after start of treatment AND 
persistent C ≥ 80 mg/L from 1 h 
after start of treatment 
 5 (27.8%)   
Page 29 of 30
 30 
C > 16 mg/L reached within 1 h 
after start of treatment AND 
persistent C ≥ 16 mg/L from 1 h 
after start of treatment 
 15 (83.3%)   
0% of samples C ≥ 80 mg/L from 1 
h after start of treatment, per 
patient (n = 18) 
 2 (11.1%)   
0% of samples C ≥ 16 mg/L from 1 
h after start of treatment, per 
patient (n = 18) 
 0 (0%)   
Cmax, maximum concentration; Cmin, minimum concentration; C, concentration. 
a Duration of treatment with piperacillin, including sampling of piperacillin concentrations 
per protocol. 
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